The proposed research concerns the status of cholinergic synapses in the cerebral cortex during aging and the progression of Alzheimer's disease (AD), studies of normal and altered neurochemical mechanisms of pre- and postsynaptic muscarine receptors, and measurements with agents which may prevent or reverse cholinergic dysfunction in aging and AD.
Seven aims are proposed.
In aim I, new assays for presynaptic M2 and postsynaptic M1 and nicotine receptors will be used to assess these sited in 7 bilateral cortical regions of normal, aged and AD human brains, for the first time. It is likely that an increasing M1/M2 ratio will correlate closely with increasing neuropathology, and prove to be a useful neurochemical measure of cholinergic denervation. The same brains and regions will be used in aim 2 to compare the laminar cortical patterns of declining M2 receptors, increasing neuritic plaques, and remaining postsynaptic receptors, by silver-staining and new autoradiographic (AR) techniques. These studies test hypotheses that changes in cholinergic synapses may be an invariant feature of AD, and that they correlate spatially and temporally with the appearance of plaques as AD progresses. A library of tissue blocks will be obtained for future work with other kinds of synapses.
In aim 3, the efficacy of various M1-agonists will be estimated from their ability to promote a GppNHp-sensitive high affinity state of these receptors, both for aim 7 and for possible AD therapy. Effective M1-agonists have not yet been tried in AD.
In aim 4, the conditions necessary for estradiol to upregulate cortical cholinergic nerves will be explored in rats, using sex, time, dose and age as variables. Long term goals include trials of estradiol to prevent changes in cholinergic synapses in aging animals and AD.
Aim 5 explores downregulation of nicotine receptors in the rat cortex with respect to nicotine dosage and timing. The intent is to see whether these receptors can be repeatedly activated without causing desensitization.
Aim 6 concerns the reason for a major loss of high affinity agonist binding to cortical M2 receptors in old Fisher 344 rats, despite normal M2 levels. Pertussis toxin-catalyzed 32-ADP-ribosylation will be used to assess levels of a guanine nucleotide binding protein (Gi) associated with M2, and attempts will be made to stabilize altered agonist-M2-Gi ternary complexes for further studies.
Aim 7 is an attempt to isolate and identify the nucleotide binding proteins associated specifically with rabbit brain M1 and M2, via soluble ternary complexes of each. Long term goals include detailed neurochemical work with the M1 postsynaptic mechanism, which promotes phosphoinositide metabolism and changes in cytosolic calcium, and may control growth.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG006170-03
Application #
3117040
Study Section
Neurology B Subcommittee 1 (NEUB)
Project Start
1986-05-01
Project End
1991-04-30
Budget Start
1988-05-01
Budget End
1989-04-30
Support Year
3
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Miami School of Medicine
Department
Type
Schools of Medicine
DUNS #
City
Miami
State
FL
Country
United States
Zip Code
33101
Liang, J; Gutierrez-Ford, C; Potter, L T (2001) Sustained unilateral blockade of rat striatal M(1) muscarinic receptors with m1-toxin1 in vivo. Brain Res 921:211-8
Krajewski, J L; Dickerson, I M; Potter, L T (2001) Site-directed mutagenesis of m1-toxin1: two amino acids responsible for stable toxin binding to M(1) muscarinic receptors. Mol Pharmacol 60:725-31
Santiago, M P; Potter, L T (2001) Biotinylated m4-toxin demonstrates more M4 muscarinic receptor protein on direct than indirect striatal projection neurons. Brain Res 894:12-20
Carsi, J M; Valentine, H H; Potter, L T (1999) m2-toxin: A selective ligand for M2 muscarinic receptors. Mol Pharmacol 56:933-7
Purkerson, S L; Potter, L T (1998) Use of antimuscarinic toxins to facilitate studies of striatal m4 muscarinic receptors. J Pharmacol Exp Ther 284:707-13
Liang, J S; Carsi-Gabrenas, J; Krajewski, J L et al. (1996) Anti-muscarinic toxins from Dendroaspis angusticeps. Toxicon 34:1257-67
Max, S I; Liang, J S; Potter, L T (1993) Stable allosteric binding of m1-toxin to m1 muscarinic receptors. Mol Pharmacol 44:1171-5
Max, S I; Liang, J S; Valentine, H H et al. (1993) Use of m1-toxin as a selective antagonist of m1 muscarinic receptors. J Pharmacol Exp Ther 267:480-5
Max, S I; Liang, J S; Potter, L T (1993) Purification and properties of m1-toxin, a specific antagonist of m1 muscarinic receptors. J Neurosci 13:4293-300
Pearce, B D; Potter, L T (1991) Coupling of m1 muscarinic receptors to G protein in Alzheimer disease. Alzheimer Dis Assoc Disord 5:163-72

Showing the most recent 10 out of 13 publications